PALO ALTO, Calif.--(BUSINESS WIRE)--Nov. 1, 2004--Agilent
Technologies Inc. (NYSE:A) today announced the completion of its
acquisition of Silicon Genetics, a leading provider of software
solutions for life science discovery. Agilent and Silicon Genetics had
announced an acquisition agreement Aug. 23, 2004. Financial details of
the agreement were not disclosed.
Silicon Genetics, based in Redwood City, Calif., has been
recognized as one of the fastest-growing technology companies in North
America. Its customers include more than 600 leading pharmaceutical
companies, academic institutions and major research organizations
around the world. With the addition of Silicon Genetics' genomics data
analysis and management tools to its portfolio, Agilent will become a
market leader in life science informatics.
Together, Silicon Genetics and Agilent will form a life science
informatics team that will create products spanning DNA, RNA, protein
and pathway applications. The team will sell and support the products
developed by Silicon Genetics, the Rosetta Resolver and Luminator gene
expression data analysis systems, the Agilent Spectrum Mill proteomics
workbench and the Agilent Synapsia informatics workbench. The team
will also work closely with customers and partners to develop
functionality for new life science research applications.
Most of Silicon Genetics' 50 employees have joined Agilent and are
part of the company's Life Sciences and Chemical Analysis business in
Santa Clara, Calif.
More information about the GeneSpring, Signet and Varia products
developed by Silicon Genetics is still available online at
www.silicongenetics.com.
Agilent in Life Sciences
Agilent's Life Sciences and Chemical Analysis (LSCA) business is a
world-leading provider of instruments, supplies, software and services
to the life science and chemical analysis markets. In 2003, these
markets accounted for approximately 40 percent and 60 percent
respectively of LSCA's $1.2 billion in revenue. Agilent's LSCA
business is a global organization with 3,700 employees, five
international manufacturing sites, and worldwide sales and support
services to more than 22,000 customer organizations in more than 70
countries. It is a leading provider of microarray, microfluidic,
liquid chromatography, gas chromatography and mass spectrometry-based
solutions to pharmaceutical, biotech, academic, government and
chemical organizations.
About Agilent Technologies
Agilent Technologies Inc. (NYSE:A) is a global technology leader
in communications, electronics, life sciences and chemical analysis.
The company's 28,000 employees serve customers in more than 110
countries. Agilent had net revenue of $6.1 billion in fiscal year
2003. Information about Agilent is available on the Web at
www.agilent.com.
Forward-Looking Statements
This news release contains forward-looking statements, including,
without limitation, statements relating to the effect of the
transaction on Agilent's financial condition and future business
strategies, that involve risks and uncertainties that could cause
results of Agilent Technologies to differ materially from management's
current expectations. These include the timing and successful
completion of product development, integration issues, the risks that
anticipated benefits are not realized and the ability to retain
Silicon Genetics' customers and employees as well as the risks and
uncertainties that are detailed in Agilent's Annual Report on Form
10-K for the year ended Oct. 31, 2003, and its Quarterly Report on
Form 10-Q for the quarter ended July 31, 2004, as filed with the
Securities and Exchange Commission.
NOTE TO EDITORS: Further technology, corporate citizenship and
executive news is available on the Agilent news site at
www.agilent.com/go/news.
CONTACT: Agilent Life Sciences
Christina Maehr, 408-553-7205
christina_maehr@agilent.com
or
Agilent Corporate
Michele Drake, 650-752-5296
michele_drake@agilent.com
SOURCE: Agilent Technologies Inc.